# Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

> **NCT05372016** · PHASE3 · COMPLETED · sponsor: **Shanghai Bovax Biotechnology Co., Ltd.** · enrollment: 1200 (actual)

## Conditions studied

- HPV Infections
- Cervical Cancer
- Vulvar Cancer
- Vaginal Cancer
- CIN1
- CIN2
- CIN3
- VaIN1
- VaIN2
- VaIN3
- Genital Wart
- VIN 1
- VIN 2
- VIN 3
- AIS

## Interventions

- **BIOLOGICAL:** Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
- **BIOLOGICAL:** Active Comparator: GARDASIL ®9

## Key facts

- **NCT ID:** NCT05372016
- **Lead sponsor:** Shanghai Bovax Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-19
- **Primary completion:** 2022-06-17
- **Final completion:** 2022-06-17
- **Target enrollment:** 1200 (ACTUAL)
- **Last updated:** 2023-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05372016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05372016, "Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05372016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*